Use of Inj. Clonidine to reduce use of painkillers during surgery and to reduce blood loss.

Balanced Anesthesia Using Intravenous Clonidine in Breast Conservation Surgery with Minimal Blood Loss : A Randomized Control trial.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/10/021505

Enrollment

Registered

2019-10-01

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Inj. Clonidine: Route of administration : Intravenous Dose : 2 microgram/kg of body weight Frequency : Stat dose Duration of Therapy : Single dose Control Intervention1: Labetalol Fenta

Eligibility

Inclusion criteria

Inclusion criteria: 1. Operable Breast Cancer Patients undergoing Breast Conservation Surgery in Adjuvant and Neoadjuvant setting. 2. Age 18 yrs â?? 80 yrs 3. Patientâ??s ASA between I â?? III 4. ECOG Performance Status 5. Estimated Life Expectancy > 6 months based on clinical evaluation by the Investigator. 6. No persistent toxicities from prior medications at screening. 7. Able to comply to study requirement in opinion of Investigator. 8. Hematology, Sr. Creatinine and R BSL within Normal Limits 9. Negative Pregnancy tests in sexually active women 10. Patient able to understand and provide written informed consent prior to participation in the study.

Exclusion criteria

Exclusion criteria: 1. Uncontrolled DM with Autonomic Dysfunction 2. Uncontrolled HTN 3. IHD 4. Heart Block 5. Patients on Beta Blockers 6. History of CVA or DVT within last 3 months. 7. Pregnant or Breast Feeding Women 8. Hypersensitivity to Inj. Clonidine, Inj. Labetelol, Inj. Fentanyl. 9. Active Opprtunistic Infections. 10. Impaired Cardiac Function within last 6 months. 11. Drug Abuse â?? Tobacco, Alcohol or any other recreational drugs 12. Positive or reactive test for HIV, HAV, HCV or HBsAg 13. Receipt of any other IP or participation in other drug trial within 30 days or 5 half lives , whichever is greater, prior to receiving drug in this study. 14. Any other primary tumours. 15. Other serious illness that would prohibit understanding and giving informed consent.

Design outcomes

Primary

Measure	Time frame
Blood loss, Need of Analgesia.Timepoint: At the End of Study	—

Secondary

Measure	Time frame
Achievement of MAP 60-70 mm of Hg or % reduction in MAPTimepoint: At the End of Study	—

Countries

India

Contacts

Public ContactDr Nayana Kulkarni

HCG Manavata Cancer Centre

nayana73@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026